Sidewinder Therapeutics Secures $137 Million in Series B Funding Led by Novartis and OrbiMed to Advance Bispecific ADC Programs

Sidewinder Therapeutics has secured $137 million in Series B funding to advance its bispecific antibody-drug conjugate (ADC) programs into clinical trials. The funding round was led by Novartis and OrbiMed, with participation from other investors.

The company plans to use the capital to further develop its pipeline of bispecific ADCs, which are designed to target cancer cells more precisely while minimizing damage to healthy tissue. This approach combines the specificity of antibodies with the potency of cytotoxic drugs, aiming to improve treatment outcomes for patients. The investment marks a significant step in Sidewinder’s efforts to bring these innovative therapies closer to clinical evaluation.

Newsflash | Powered by GeneOnline AI

Source: GO-AI-ne1

For any suggestion and feedback, please contact us.

Date: April 8, 2026

Author

GOAI